Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lung cancer clot risk under microscope in 2,400-Patient study

NCT ID NCT06950697

First seen May 04, 2026 · Last updated May 23, 2026 · Updated 6 times

Summary

This study watches 2,400 lung cancer patients who are getting immunotherapy (immune checkpoint inhibitors) to see how often they develop dangerous blood clots. Researchers will compare patients who get clots with those who don't, looking for clues in their health records and lab tests. The goal is to build a simple tool that doctors can use to predict and prevent clots in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VENOUS THROMBOEMBOLISM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Chaoyang Hospital, Capital Medical University

    RECRUITING

    Beijing, China

  • Beijing Luhe Hospital, Capital Medical University

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • China-japan Friendship Hospital

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, Henan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Fourth Hospital of Inner Mongolia Autonomous Region

    RECRUITING

    Hohhot, Inner Mongolia, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.